Current status and progress of diagnosis and treatment in thyroid disease

doi:10.3969/j.issn.1004-583X.2016.03.012

Abstract

Abstract: The detection rate of thyroid nodule is increasing year by year.The first problem is to clear and identify its evil nature,and corresponding treatment methods have been standardized, improved and innovated.The incidence of papillary thyroid cancer is increasing. The indications for surgery to master standardized operation, the nano-carbon parathyroid negative imaging techniques and applications to detect recurrent laryngeal nerve injury become the focus to protect the parathyroid gland and reduce the laryngeal recurrent nerve injury. In addition, some targeted drugs treatment for advanced thyroid cancer are also continuing to explore and research.

Key words: thyroid neoplasms, nanotechnology, recurrent laryngeal nerve, immunotoxins

CLC Number:

R736.1

Liao Haiying, Zhu Peiling, Zhang Kaili, Hu Zhigang. Current status and progress of diagnosis and treatment in thyroid disease[J]. Clinical Focus, 2016, 31(3): 282-285.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.03.012

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I3/282

References

[1] 卢珊, 马向华, 沈捷. 甲状腺结节良恶性鉴别的研究进展[J]. 医学综述, 2010, 16(6): 859-862.
[2] 钟凯. 甲状腺癌与甲状腺结节钙化的关系探讨[J]. 中国现代医生, 2012, 50(23): 38-39, 41.
[3] 周永昌, 郭万学. 超声医学[M].4版. 北京:科学技术文献出版社, 2002: 158-159.
[4] Suen KC, Quenville NF. Fine needle aspiration biopsy of the thyroid gland: a study of 304 cases[J].J Clin Pathol, 1983, 36(9): 1036-1045.
[5] 谢朝艳, 杜心芳, 顾世明, 等. 超声引导粗针活检技术在甲状腺肿块诊断中的价值[J]. 临床医学, 2007, 27(1): 8-9.
[6] Camargo RY, Tonimori EK. Usefulness of ultrasound in the diagnosis and management of well-differentiated thyroid carcinoma[J]. Arq Bras Endocrinol Metabol, 2007, 51(5): 783-792.
[7] Cashman EC, Bresnihan M, Timon C, et al. Patients’ quality of life post thyroidectomy[J]. B-ENT, 2011, 7(4): 261-265.
[8] Wilhelm SM, Mchenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States[J]. World J Surg, 2010, 34(6): 1261-1264.
[9] Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma:a single-institution experience using aggressive multimodal therapy[J]. Thyroid, 2011, 21(1): 25-30.
[10] 何霞云.甲状腺未分化癌的综合治疗[J]. 中国实用外科杂志, 2011, 31(5): 401-404.
[11] Passler C, Scheuba C, Prager G, et al. Anaplastic (Undifferentiated) thyroid carcinoma (ATC). A retrospective analysis[J]. Langenbecks Arch Surg, 1999, 384 (3): 284-293.
[12] Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy[J]. Thyroid, 2011, 21 (1):25-30.
[13] Roche B, Larroumets G, Dejax C, et al. Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the literature[J]. Ann Endocrinol (Paris), 2010, 71(1):38-45.
[14] Swaak-Kragten AT, de Wilt JH, Schmitz PL, et al. Multimodality treatment for anaplastic thyroid carcinoma treatment outcome in 75 patients[J]. Radiother Oncol, 2009,92(1): 100-104.
[15] Hay ID, Thompson GB, Grant CS, et al.Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940‐1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients [J]. World J Surg, 2002, 26(8): 879- 885.
[16] Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic Review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer [J].Endocrinol Metab Clin North Am, 2008, 37(2): 457- 480.
[17] Brierley J, Tsang R, Panzarella T, et al. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years[J]. Clin Endocrinol(Oxf), 2005, 63(4): 418- 427.
[18] 范西红, 贺青卿, 张小桥, 等. 全甲状腺切除术治疗甲状腺癌102 例体会[J]. 中华普通外科杂志, 2005,20(7): 452-453.
[19] Thomusch O, Machens A, Sekulla C, et al. The impat of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients[J]. Surgery, 2003,133(2):180-185.
[20] 马峻峰, 唐波, 李铁汉. 促甲状腺激素抑制疗法在分化型甲状腺癌治疗中的作用[J]. 中国普外基础与临床杂志,2009, 16(5): 348-355.
[21] Sanders LE, Silverman M. Follicular and Hürthle cell cacinoma: predicting outcome and directing therapy[J].Surgery,1998,124 (6): 967-974.
[22] Middendorp M, Criblwald F. UP date on recent deve1opments in the therapy of diferentiated thyroid cancer[J]. Sermin Nucl Med, 2010, 40(2): 145-152.
[23] Matuszezyk A, Petersenn S, Bockiseh A, et al. Chemotherapy with doxorubicin in progressive medulary and thyroid earcinoma of the follicular epithelium[J]. Horm Metab Res, 2008, 40(3): 210-213.
[24] Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors[J]. Endocr Rev, 2010, 31(4): 578-599.
[25] 钱碧云,何敏,高明, 等.2002~2006年天津市甲状腺癌发病率与26年间长期趋势分析[J]. 中华普通外科杂志, 2011, 26(4):275-278.
[26] 李伟,徐亮. 纳米碳在胃癌淋巴靶向化疗中的应用研究进展[J]. 泸州医学院学报, 2009, 32(4):439-441.
[27] 姜华, 李玺, 刘仁斌, 等. 喉肌电活动实时监测喉返神经在再次甲状腺手术中的应用[J/CD]. 中华普通外科学文献: 电子版, 2014, 8(1): 4-7.
[28] Sturgeon C, Sturgeon T, Angelos P. Neuromonitoring in thyroid surgery: attitudes, usage patterns, and predictors of use among endocrine surgeons[J]. World J Surg, 2009, 33(3): 417-425.